相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials
T. Bieber et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2021)
The molecular features of normal and atopic dermatitis skin in infants, children, adolescents, and adults
Yael Renert-Yuval et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2021)
Efficacy and Safety of Abrocitinib in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis (AD): Results From the Phase 3 JADE TEEN study
Lawrence Eichenfield et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2021)
Baricitinib in patients with moderate-tosevere atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5)
Eric L. Simpson et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)
Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials
Brett King et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2021)
Patient-Reported Symptoms and Disease Impacts in Adults With Moderate-to-Severe Atopic Dermatitis: Results From a Phase 2b Study With Abrocitinib
Eric L. Simpson et al.
DERMATITIS (2021)
Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate-to-severe atopic dermatitis from the BREEZE-AD7 Phase 3 randomized trial
A. Wollenberg et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2021)
Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis
Thomas Bieber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Long-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders An Extension Study of 2 Randomized Clinical Trials
Jonathan I. Silverberg et al.
JAMA DERMATOLOGY (2021)
26900 A phase 2b trial evaluating the efficacy of delgocitinib cream for the treatment of chronic hand eczema (CHE) using and validating the Hand Eczema Severity Index (HECSI)
Per Soerensen et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)
28200 Effects of ruxolitinib cream on work productivity and activity impairment in patients with atopic dermatitis: Pooled results from two phase 3 studies
Lawrence F. Eichenfield et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)
25977 Selected infection topics in adult patients with moderate-to-severe atopic dermatitis treated with baricitinib
Melinda Gooderham et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)
25094 Delgocitinib ointment in pediatric patients with atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study
Hidemi Nakagawa et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)
26691 Rapid and concurrent improvements in the signs and symptoms of atopic dermatitis with baricitinib in the phase 3 study, BREEZE-AD5
Peter Lio et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double- blind, randomised controlled phase 3 trials
Emma Guttman-Yassky et al.
LANCET (2021)
Efficacy and safety of topical delgocitinib in patients with chronic hand eczema: data from a randomized, double-blind, vehicle-controlled phase IIa study
M. Worm et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Treatment of atopic dermatitis with ruxolitinib cream (JAKI/JAK2 inhibitor) or triamcinolone cream
Brian S. Kim et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)
Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial
Emma Guttman-Yassky et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)
Evolution of pathologic T-cell subsets in patients with atopic dermatitis from infancy to adulthood
Tali Czarnowicki et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)
Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis A Phase 3 Randomized Clinical Trial
Eric L. Simpson et al.
JAMA DERMATOLOGY (2020)
Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phaseIIItrials
E. L. Simpson et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Janus kinase inhibitor delgocitinib suppresses pruritus and nerve elongation in an atopic dermatitis murine model
Yasuo Yamamoto et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2020)
Long-term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis
Hidemi Nakagawa et al.
JOURNAL OF DERMATOLOGY (2020)
Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study
Hidemi Nakagawa et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Effects of ruxolitinib cream on pruritus and quality of life in atopic dermatitis: Results from a phase 2, randomized, dose-ranging, vehicle- and active-controlled study
Brian S. Kim et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to < 24 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE 1)
Joel Schlessinger et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2020)
No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis
Amy S. Paller et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis
Eric Simpson et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis A Randomized Clinical Trial
Jonathan Silverberg et al.
JAMA DERMATOLOGY (2020)
Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial
Amy S. Paller et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
Eric L Simpson et al.
LANCET (2020)
Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis A Randomized Clinical Trial
Kristian Reich et al.
JAMA DERMATOLOGY (2020)
16089 Safety of ATI-502, a novel topical JAK1/3 inhibitor, in adults with moderate to severe atopic dermatitis: Results from a phase 2a open-label trial
Stacy Smith et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Atopic dermatitis: Tofacitinib, an option for refractory disease
Sineida Berbert Ferreira et al.
CLINICAL CASE REPORTS (2020)
Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study
Emma Guttman-Yassky et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
A systematic review and meta-analysis of the regional and age-related differences in atopic dermatitis clinical characteristics
Yik Weng Yew et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Comorbidities and the impact of atopic dermatitis
Jonathan I. Silverberg
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2019)
The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study
R. Bissonnette et al.
BRITISH JOURNAL OF DERMATOLOGY (2019)
Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis
G. Yosipovitch et al.
BRITISH JOURNAL OF DERMATOLOGY (2019)
Pain Is a Common and Burdensome Symptom of Atopic Dermatitis in United States Adults
Jonathan I. Silverberg et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2019)
Phase 2 clinical study of delgocitinib ointment in pediatric patients with atopic dermatitis
Hidemi Nakagawa et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2019)
Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis A Phase 2 Randomized Clinical Trial
Melinda J. Gooderham et al.
JAMA DERMATOLOGY (2019)
Atopic dermatitis endotypes and implications for targeted therapeutics
Tali Czarnowicki et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2019)
Atopic Dermatitis in America Study: A Cross-Sectional Study Examining the Prevalence and Disease Burden of Atopic Dermatitis in the US Adult Population
Zelma C. Chiesa Fuxench et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2019)
A retrospective study: Application site pain with the use of crisaborole, a topical phosphodiesterase 4 inhibitor
Christine Pao-Ling Lin et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Health Utility Scores of Atopic Dermatitis in US Adults
Jonathan Silverberg et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2019)
A novel JAK inhibitor JTE-052 reduces skin inflammation and ameliorates chronic dermatitis in rodent models: Comparison with conventional therapeutic agents
Atsuo Tanimoto et al.
EXPERIMENTAL DERMATOLOGY (2018)
Atopic dermatitis yardstick: Practical recommendations for an evolving therapeutic landscape
Mark Boguniewicz et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2018)
Atopic dermatitis in US adults Epidemiology, association with marital status, and atopy
Tammy Hua et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2018)
Patient burden and quality of life in atopic dermatitis in US adults GI A population-based cross-sectional study
Jonathan I. Silverberg et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2018)
Efficacy and safety of topical JTE-052, a Janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: a phase II, multicentre, randomized, vehicle-controlled clinical study
H. Nakagawa et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
Association of atopic dermatitis with allergic, autoimmune, and cardiovascular comorbidities in US adults
Jonathan I. Silverberg et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2018)
Itch: From mechanism to (novel) therapeutic approaches
Gil Yosipovitch et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2018)
Novel concepts of prevention and treatment of atopic dermatitis through barrier and immune manipulations with implications for the atopic march
Tali Czarnowicki et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)
The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies
Patrick M. Brunner et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)
JAK inhibitors in dermatology: The promise of a new drug class
William Damsky et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial
Andrew Blauvelt et al.
LANCET (2017)
Selected comorbidities of atopic dermatitis: Atopy, neuropsychiatric, and musculoskeletal disorders
Jonathan I. Silverberg
CLINICS IN DERMATOLOGY (2017)
Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases
Daniella M. Schwartz et al.
NATURE REVIEWS RHEUMATOLOGY (2016)
Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial
R. Bissonnette et al.
BRITISH JOURNAL OF DERMATOLOGY (2016)
Burden of Sleep and Fatigue in US Adults With Atopic Dermatitis
Sherry H. Yu et al.
DERMATITIS (2016)
Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults
Amy S. Paller et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2016)
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
E. L. Simpson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Genetic and epigenetic studies of atopic dermatitis
Lianghua Bin et al.
ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY (2016)
The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention
John J. O'Shea et al.
ANNUAL REVIEW OF MEDICINE, VOL 66 (2015)
Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate
Lauren L. Levy et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2015)
Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases
James D. Clark et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Guidelines of care for the management of atopic dermatitis
Robert Sidbury et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2014)
Guidelines of care for the management of atopic dermatitis Section 2. Management and treatment of atopic dermatitis with topical therapies
Lawrence F. Eichenfield et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2014)
Association between severe eczema in children and multiple comorbid conditions and increased healthcare utilization
Jonathan I. Silverberg et al.
PEDIATRIC ALLERGY AND IMMUNOLOGY (2013)
New Insights into Atopic Dermatitis: Role of Skin Barrier and Immune Dysregulation
Donald Y. M. Leung
ALLERGOLOGY INTERNATIONAL (2013)
Progressive activation of TH2/TH22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis
Julia K. Gittler et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2012)
Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)
Kamran Ghoreschi et al.
JOURNAL OF IMMUNOLOGY (2011)
Endogenous antimicrobial peptides and skin infections in atopic dermatitis
PY Ong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis
S Reitamo et al.
ARCHIVES OF DERMATOLOGY (2000)
分享论文
